The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(SUPPL.8):8–11. doi:10.1093/annonc/mds256
   Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271. doi:10.1146/annurev-immunol-031210-101324
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65(10):1228–1238. doi:10.1373/clinchem.2019.303644
   PubMed Web of Science ®Google Scholar
• Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(S2):87–97. doi:10.3747/co.27.5223
   Google Scholar
• Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36(10):2638–2678. doi:10.1007/s12325-019-01051-z
   PubMed Web of Science ®Google Scholar
• Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.00563
   Web of Science ®Google Scholar
• Wang D, Du Bois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36(10):1085–1093. doi:10.1093/carcin/bgv123
   PubMed Web of Science ®Google Scholar
• Michels N, van Aart C, Morisse J, Huybrechts I. Chronic inflammation toward cancer incidence: an epidemiological systematic review. J Glob Oncol. 2018;4(Supplement 2):24s–24s. doi:10.1200/jgo.18.56200
   Google Scholar
• Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–2380. doi:10.1002/ijc.23173
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. 2018;8:1–16. doi:10.3389/fonc.2018.00049
   PubMed Web of Science ®Google Scholar
• Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709–4721. doi:10.1002/cam4.2327
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;22(Box1)
   Google Scholar
• Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–220.
   PubMed Web of Science ®Google Scholar
• Zhu S, Yang N, Wu J, et al. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Pharmacol Res. 2020;159:519. doi:10.1016/j.phrs.2020.104980
   Web of Science ®Google Scholar
• Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012;22(4):307–318. doi:10.1016/j.semcancer.2012.02.008
   PubMed Web of Science ®Google Scholar
• Schwitalla S, Fingerle AA, Cammareri P, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152(1–2):25–38. doi:10.1016/j.cell.2012.12.012
   PubMed Web of Science ®Google Scholar
• Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019;10(4):365–381. doi:10.1007/s13167-019-00194-x
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi:10.1038/s41568-019-0116-x
   PubMed Web of Science ®Google Scholar
• Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med. 2018;12(4):426–439.
   PubMed Web of Science ®Google Scholar
• Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med. 2015;12(2):74–78. doi:10.7497/j.issn.2095-3941.2015.0022
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the t cell-inflamed versus non-t cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
   PubMed Web of Science ®Google Scholar
• Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64(8):2865–2873.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326–341.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6. doi:10.1038/ncomms8458
   Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74-80.
   Google Scholar
• Lapuente-Santana O, Eduati F. Toward systems biomarkers of response to immune checkpoint blockers. Front Oncol. 2020;10:1–9. doi:10.3389/fonc.2020.00001
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):1–17. doi:10.1186/s12943-018-0930-x
   PubMedGoogle Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Guo Q, Huang F, Goncalves C, Del Rincón SV, Miller WH Translation of cancer immunotherapy from the bench to the bedside. 143 Adv Cancer Res Elsevier Inc 2019 1–62 p
   PubMed Web of Science ®Google Scholar
• Vajaitu C, Draghici CC, Solomon I, et al. The central role of inflammation associated with checkpoint inhibitor treatments. J Immunol Res. 2018;2018:2018. doi:10.1155/2018/4625472
   Web of Science ®Google Scholar
• PDL1 F 2. pd-l1-ihc-22c3-pharmdx-p150013s014. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/pd-l1-ihc-22c3-pharmdx-p150013s014. Accessed March 3, 2021.
   Google Scholar
• FDA2. pd-l1-ihc-28-8-pharmdx-p150025s013. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/pd-l1-ihc-28-8-pharmdx-p150025s013. Accessed March 3, 2021.
   Google Scholar
• Checkmate 275. NCT02387996. Available from: https://clinicaltrials.gov/ct2/show/NCT02387996. Accessed March 3, 2021.
   Google Scholar
• Keynote059. NCT02335411. Available from: https://clinicaltrials.gov/ct2/show/NCT02335411. Accessed March 3, 2021.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. doi:10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, Phase 2 trial. Lancet Oncol. 2017;18(3):312–322. doi:10.1016/S1470-2045(17)30065-7
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:962–971. doi:10.1016/j.eururo.2017.02.010
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):1–8.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020;38(23):2658–2666. doi:10.1200/JCO.19.01213
   PubMed Web of Science ®Google Scholar
• Le DT, Kim TW, van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.02107
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage iv or recurrent non–small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. doi:10.1056/NEJMoa1613493
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Tan HN, Rodriguez CC, Monte KA, Tan PG, Cornelio GDH. 106P Immune checkpoint proteins as a prognostic biomarker of overall survival in non-small cell lung cancer: a meta-analysis and systematic review. Ann Oncol. 2020;31:S283. doi:10.1016/j.annonc.2020.08.227
   PubMed Web of Science ®Google Scholar
• Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8(1):1–17. doi:10.1186/s40364-020-00209-0
   PubMed Web of Science ®Google Scholar
• Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (80-). 2018;359(6375):582–587. doi:10.1126/science.aao4572
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–1271.e11. doi:10.1016/j.cell.2017.10.001
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, Gagliato DDM, Kurzrock R. ll review the challenges of tumor mutational burden as an immunotherapy biomarker; 2020. 2021.
   Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031. doi:10.1038/nbt.2696
   PubMed Web of Science ®Google Scholar
• Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagno. 2015;17(3):251–264. doi:10.1016/j.jmoldx.2014.12.006
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829. doi:10.1056/NEJMoa1604958
   PubMed Web of Science ®Google Scholar
• Huyghe N, Baldin P, Van Den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep. 2020;8(1):11–24. doi:10.1093/gastro/goz061
   Google Scholar
• Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem. 2006;281(41):30305–30309. doi:10.1074/jbc.R600022200
   PubMed Web of Science ®Google Scholar
• Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int. 2017;2017:1–8. doi:10.1155/2017/4719194
   Web of Science ®Google Scholar
• Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746–756. doi:10.1002/cam4.1372
   PubMed Web of Science ®Google Scholar
• Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J Mol Diagno. 2008;10(4):293–300. doi:10.2353/jmoldx.2008.080031
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–618. doi:10.1200/JCO.2005.01.086
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-0863
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• FDA FDA-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature. Accessed March 3, 2021.
   Google Scholar
• FDA-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer. Accessed March 3, 2021.
   Google Scholar
• Carethers JM. Abstract IA4: the role of inflammation and DNA mismatch repair in colorectal cancer. Cancer Res. 2017;77(22Supplement):IA4LP–IA4.
   Google Scholar
• Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (80-). 2006;313(5795):1960–1964. doi:10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Marliot F, Chen X, Kirilovsky A, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J Immunother Cancer. 2020;8(1):13–15. doi:10.1136/jitc-2019-000272
   Web of Science ®Google Scholar
• Yoon HH, Shi Q, Heying EN, et al. Intertumoral heterogeneity of CD3þ and CD8þ T-cell densities in the microenvironment of DNA mismatch-repair–deficient colon cancers: implications for prognosis. Clin Cancer Res. 2019;25(1):125–133. doi:10.1158/1078-0432.CCR-18-1984
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Huebner LJ, Finnes HD, et al. Intratumoral CD3 + and CD8 + T-Cell densities in patients with DNA mismatch repair–deficient metastatic colorectal cancer receiving programmed cell death-1 blockade. JCO Precis Oncol. 2019;3:1–7.
   PubMed Web of Science ®Google Scholar
• NCT03608046. Available from: https://clinicaltrials.gov/ct2/show/NCT03608046. Accessed March 3, 2021.
   Google Scholar
• Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol. 2019;20(5):e274–83. doi:10.1016/S1470-2045(19)30172-X
   PubMed Web of Science ®Google Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:11. doi:10.2147/OTT.S153290
   Web of Science ®Google Scholar
• Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–146. doi:10.1016/j.critrevonc.2017.06.002
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Templeton A, et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792–2799. doi:10.1002/cam4.878
   PubMed Web of Science ®Google Scholar
• Buisan O, Orsola A, Oliveira M, et al. Role of inflammation in the perioperative management of urothelial bladder cancer with squamous-cell features: impact of neutrophil-to-lymphocyte ratio on outcomes and response to neoadjuvant chemotherapy. Clin Genitourin Cancer. 2017; 15:e697–e706. doi: 10.1016/j.clgc.2017.01.024
   PubMed Web of Science ®Google Scholar
• Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2016;174(1):146–151. doi:10.1111/bjd.14155
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503. doi:10.1038/s41568-020-0281-y
   PubMed Web of Science ®Google Scholar
• Kovács T, Mikó E, Ujlaki G, Sári Z, Bai P. The microbiome as a component of the tumor microenvironment. Adv Exp Med Biol. 2020;1225:137–153.
   PubMed Web of Science ®Google Scholar
• Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science (80-). 2020;368(6494):973–980. doi:10.1126/science.aay9189
   PubMed Web of Science ®Google Scholar
• Zhao K, Hu Y. Microbiome harbored within tumors: a new chance to revisit our understanding of cancer pathogenesis and treatment. Signal Transduct Target Ther. 2020;5(1):2–4. doi:10.1038/s41392-020-00244-1
   PubMed Web of Science ®Google Scholar
• Lee KA, Shaw HM, Bataille V, Nathan P, Spector TD. Role of the gut microbiome for cancer patients receiving immunotherapy: dietary and treatment implications. Eur J Cancer. 2020;138:149–155. doi:10.1016/j.ejca.2020.07.026
   PubMed Web of Science ®Google Scholar
• Wang J, Yang HR, Wang DJ, Wang XX. Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors (Review). Oncol Lett. 2020;20(6):1–9. doi:10.3892/ol.2020.11862
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):S12–6. doi:10.1038/nature24462
   Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar